322 related articles for article (PubMed ID: 33980831)
1. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Mikhael J; Belhadj-Merzoug K; Hulin C; Vincent L; Moreau P; Gasparetto C; Pour L; Spicka I; Vij R; Zonder J; Atanackovic D; Gabrail N; Martin TG; Perrot A; Bensfia S; Weng Q; Brillac C; Semiond D; Macé S; Corzo KP; Leleu X
Blood Cancer J; 2021 May; 11(5):89. PubMed ID: 33980831
[No Abstract] [Full Text] [Related]
2. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
4. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Richardson PG; Beksaç M; Špička I; Mikhael J
Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date.
Richter J; Sanchez L; Thibaud S
Semin Oncol; 2020; 47(2-3):155-164. PubMed ID: 32446599
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
8. Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.
Chehab S; Zhang C; Panjic EH; Chen Z; Kaufman JL; Lonial S; Nooka A; Harvey RD
Cancer; 2018 Nov; 124(22):4358-4365. PubMed ID: 30303526
[TBL] [Abstract][Full Text] [Related]
9. Current use of monoclonal antibodies in the treatment of multiple myeloma.
Varga C; Maglio M; Ghobrial IM; Richardson PG
Br J Haematol; 2018 May; 181(4):447-459. PubMed ID: 29696629
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
11. Infectious and immunological sequelae of daratumumab in multiple myeloma.
Johnsrud AJ; Johnsrud JJ; Susanibar SA; Kamimoto JJ; Kothari A; Burgess M; Van Rhee F; Rico JC
Br J Haematol; 2019 Apr; 185(1):187-189. PubMed ID: 29974956
[No Abstract] [Full Text] [Related]
12. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos M; Bringhen S; Anttila P; Capra M; Cavo M; Cole C; Gasparetto C; Hungria V; Jenner M; Vorobyev V; Ruiz EY; Yin JY; Saleem R; Hellet M; Macé S; Paiva B; Vij R
Blood; 2021 Mar; 137(9):1154-1165. PubMed ID: 33080623
[TBL] [Abstract][Full Text] [Related]
13. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Schjesvold F; Bringhen S; G Richardson P; Perrot A; Leleu X; Moreau P; A Dimopoulos M; Hulin C; Tekle C; Foster MC; Poole EM; van de Velde H; Facon T
Am J Hematol; 2021 Nov; 96(11):E423-E427. PubMed ID: 34383345
[No Abstract] [Full Text] [Related]
14. In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.
Atanackovic D; Yousef S; Shorter C; Tantravahi SK; Steinbach M; Iglesias F; Sborov D; Radhakrishnan SV; Chiron M; Miles R; Salama M; Kröger N; Luetkens T
Leukemia; 2020 Jan; 34(1):317-321. PubMed ID: 31409922
[No Abstract] [Full Text] [Related]
15. Daratumumab combination prolongs myeloma survival.
Das M
Lancet Oncol; 2016 Oct; 17(10):e422. PubMed ID: 27601427
[No Abstract] [Full Text] [Related]
16. Isatuximab for the treatment of multiple myeloma.
Goldsmith SR; Liu L; Covut F
Drugs Today (Barc); 2021 Nov; 57(11):665-675. PubMed ID: 34821880
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013.
Ribrag V; Avigan DE; Green DJ; Wise-Draper T; Posada JG; Vij R; Zhu Y; Farooqui MZH; Marinello P; Siegel DS
Br J Haematol; 2019 Aug; 186(3):e41-e44. PubMed ID: 30937889
[No Abstract] [Full Text] [Related]
18. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
19. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
[TBL] [Abstract][Full Text] [Related]
20. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]